Main Menu

The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations. Today, read about our new cancer drug access report, our childhood leukaemia appeal or opportunities for early-career researchers.

Back to top
  • ICR celebrates Royal Society of Chemistry blue plaques for cancer drug discovery

    ICR celebrates Royal Society of Chemistry blue plaques for cancer drug discovery

    The ICR has been recognised for its many successes in drug discovery through the award of blue plaques under the Royal Society of Chemistry’s Chemical Landmark scheme.

    Read more
  • Help us make childhood leukaemia a thing of the past

    Help us make childhood leukaemia a thing of the past

    Over the past 40 years, Professor Mel Greaves has been carrying out research to increase our understanding of childhood leukaemia, particularly how the most common form of this disease, acute lymphoblastic leukaemia (ALL), develops.

    Support us
  • Targeted drug – palbociclib – stops tumour growth in patients with early breast cancer

    Targeted drug – palbociclib – stops tumour growth in patients with early breast cancer

    Adding a new targeted therapy to hormone therapy halts the growth of tumour cells in women with early-stage breast cancer, new research shows.

    Read more
  • New cancer drugs taking longer to reach NHS patients

    New cancer drugs taking longer to reach NHS patients

    NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a major new analysis of regulatory data reveals.

    Read more
  • Why regulators must move with the science if we’re to get innovative new treatments to patients more quickly

    Why regulators must move with the science if we’re to get innovative new treatments to patients more quickly

    Our CEO, Professor Paul Workman, discusses the findings of the ICR's new drug access report.

    Read more
  • The 100,000 Genomes Project has finished: what were the challenges and what comes next?

    The 100,000 Genomes Project has finished: what were the challenges and what comes next?

    The 100,000 Genomes Project has reached its goal of decoding 100,000 genomes from NHS patients. We take a look at some of the challenges that had to be overcome to reach this point and ask what happens next?

    Read more
1/6

Childhood leukaemia appeal

Our latest research shows that within the next decade, we can make acute lymphoblastic leukaemia preventable. Your support will help us make this disease a thing of the past.

Donate

ICR values

Our values – developed together as an organisation – make it clear how each and every one of us work to meet our mission – to make the discoveries that defeat cancer.

Find out more

Share your story

We always want to hear from people who have a cancer story to share. Get in touch and help raise awareness of our research.

Find out more

How we work with industry

We work in close partnership with industry to take results into the clinic as soon as possible, and make sure our research delivers for cancer patients.

Find out more

The Drug Discoverer

Our Chief Executive and President, Professor Paul Workman, shares his experiences on his blog, The Drug Discoverer.

Find out more

Our scientific discoveries

For more than 100 years, the ICR has played an important role in shaping understanding of cancer and how it can be treated.

Find out more
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.